|
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Clinical research trials and Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure. Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure clinical trial. Human subjects often receive the most effective healthcare possible for their Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI (non-nucleoside reverse transcriptase inhibitor). - Plasma HIV - 1 RNA was <400 copies/ml on at least 2 documented occasions prior to viral rebound. - Have a plasma HIV - 1 RNA value >400 copies/ml and <10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks. - A CD4+ lymphocyte count less than or equal to 100. Exclusion Criteria: - Have not taken Abacavir (Ziagen or Trizivir) or tenofovir (Viread) previously. - Have not had an AIDS defining illness within 30 days of screen. - Pregnant or breast-feeding. - Specified viral genotypes upon screening. - And other inclusion or exclusion criteria to be evaluated by the physician.
Total Enrollment:
Location and Contact Information:
Study Site
Little Rock, Arkansas, 72205
United States
Study Site
Altamonte Springs, Florida, 32701
United States
Study Site
Dallas, Texas, 75219
United States
Study Site
Chicago, Illinois, 60637
United States
Study Site
Wenatchee, Washington, 98801
United States
Study Site
San Rafael, California, 94903
United States
Study Site
Des Moines, Iowa, 50309
United States
Study Site
Milwaukee, Wisconsin, 53226
United States
Study Site
Los Angeles, California, 90015
United States
Study Site
Albany, New York, 12208
United States
Study Site
Miami, Florida, 33139
United States
Study Site
Union, New Jersey, 07083
United States
Study Site
Chicago, Illinois, 60657
United States
Study Site
Stratford, Connecticut, 06614
United States
Study Site
New York City, New York, 10468
United States
Study Site
Lafayette, Indiana, 47904
United States
Study Site
Dallas, Texas, 75246
United States
Study Site
Dallas, Texas, 75248
United States
Study Site
Spokane, Washington, 99204
United States
Study Site
Tallahassee, Florida, 32303
United States
Study Site
Madison, Wisconsin, 53792
United States
Study Site
Atlanta, Georgia, 30309
United States
Study Site
Camden, New Jersey, 08103
United States
Study Site
Houston, Texas, 77004
United States
Study Site
Bronx, New York, 10461
United States
Study Site
Phoenix, Arizona, 85006
United States
Study Site
New Haven, Connecticut, 06511
United States
Study Site
Berkeley, California, 94705
United States
Study Site
Berkley, Michigan, 48072
United States
Study Site
Valhalla, New York, 10595
United States
Study Site
Philadelphia, Pennsylvania, 19107
United States
Study Site
Miami, Florida, 33136
United States
Study Site
New York City, New York, 10014
United States
Study Site
Tampa, Florida, 33614
United States
Study Site
Maywood, Illinois, 60153
United States
Study Site
Evansville, Indiana, 47710
United States
Study Site
Dallas, Texas, 75205
United States
Study Site
St. Louis Park, Minnesota, 55416
United States
Study Site
Seattle, Washington, 98122
United States
Study Site
San Francisco, California, 94114
United States
Study Site
Dallas, Texas, 75208
United States
Study Site
Chicago, Illinois, 60612
United States
Study Site
Akron, Ohio, 44304
United States
Study Site
Ft. Lauderdale, Florida, 33334
United States
Study Site
Safety Harbor, Florida, 34695
United States
Study Site
Atlantis, Florida, 33462
United States
Study Site
Decatur, Georgia, 30033
United States
Study Site
Miami, Florida, 33143
United States
Study Site
Minneapolis, Minnesota, 55404
United States
Study Site
Tulsa, Oklahoma, 74114
United States
Study Site
Los Angeles, California, 90048
United States
Study Site
Washington D.C., District of Columbia, 20037
United States
Study Site
Jacksonville, Florida, 32206
United States
Study Site
Atlanta, Georgia, 30308
United States
Study Site
Newark, New Jersey, 07102
United States
Study Site
Washington D.C., District of Columbia, 20009
United States
Study Site
Beverly Hills, California, 90211
United States
Study Site
Dallas, Texas, 75216
United States
Study Site
San Diego, California, 92101
United States
Study Site
Miami, Florida, 33139
United States
Study Site
Los Angeles, California, 90069
United States
Study Site
St. Louis, Missouri, 63108
United States
Additional Information:
Study ID Numbers: ESS 30005;
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038506
Other Hiv Infections Studies:
1. Rifabutin Therapy for the Prevention of Mycobacterium avium Complex (MAC) Bacteremia in HIV Positive Patients with CD4 Counts = or < 200: Treatment IND Study
2. Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
3. A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients with AIDS
4. A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
5. A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Related Studies:
Other HIV Infections Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
|
|
|
|
|
|
|
|